Li-Ming Gan

Li-Ming Gan is a specialist in non-invasive cardiology with broad clinical skills in cardiovascular diagnostics.

Since 2009, he has been professor in translational cardiovascular research and drug discovery at Sahlgrenska University Hospital in Göteborg, Sweden. Li-Ming actively runs academic research in the field of cardiovascular phenotyping of patients with ischemic heart disease and heart failure, as well as the development and validation of preclinical translational animal disease models.

Li-Ming joined AstraZeneca 12 years ago, where he established a preclinical translational disease platform in atherosclerosis, cardiovascular (CV) disease and heart failure area during his first five years. In 2007, Li-Ming was appointed as Disease Area Portfolio Leader and later as Science Director, responsible for bringing new drug projects into the pipeline. Between 2011 and 2013, he was CV Translational Science Director to help transfer early studies into the human setting. Here, he developed novel biomarkers and performed explorative human studies to identify and validate new drug targets.

Li-Ming is currently Vice President of Early Clinical Development in CVRM and is responsible for all clinical activities, including early explorative human experimental work, human target validation and clinical trials up to phase 2b in the cardiovascular space.